Navitoclax — The BCL-2 Inhibitor Senolytic
Navitoclax is a targeted senolytic agent originally developed as a cancer therapeutic. It holds significant relevance for longevity research due to its ability to selectively induce apoptosis in senescent cells, thereby reducing age-related inflammation and potentially restoring tissue function.
Mechanism of Action
Navitoclax (ABT-263) is a BH3 mimetic that acts as a potent inhibitor of the anti-apoptotic BCL-2 family of proteins, specifically BCL-2, BCL-xL, and BCL-w. Senescent cells often upregulate these pro-survival proteins to resist apoptosis, a phenomenon known as senescent cell anti-apoptotic pathways (SCAPs). By binding to and inhibiting BCL-2 and BCL-xL, navitoclax disrupts this survival mechanism, selectively inducing apoptosis in senescent cells. This clearance of senescent cells reduces the secretion of the senescence-associated secretory phenotype (SASP), thereby mitigating chronic sterile inflammation and tissue dysfunction associated with aging.
Human Trial Evidence
No published human longevity trials. Animal/in-vitro evidence only. Early-phase clinical trials have evaluated navitoclax primarily for oncology indications (e.g., myelofibrosis) and its safety profile in those contexts, but not for lifespan extension or healthspan improvement in healthy aging populations.
Dosing Protocol
Dosing for longevity and senolytic purposes is unestablished in humans. In animal models, doses such as 50 mg/kg/day for short cycles have been used to clear senescent cells. In human oncology trials, doses range from 150 to 325 mg/day continuously, but this regimen is not applicable to longevity. Navitoclax is an experimental, prescription-only medication.
Safety & Contraindications
Navitoclax carries significant safety risks, most notably dose-dependent and on-target thrombocytopenia (low platelet count) due to the inhibition of BCL-xL, which is essential for platelet survival. Other adverse effects observed in clinical trials include neutropenia, gastrointestinal toxicity, and fatigue. It is contraindicated in individuals with bleeding disorders or those taking anticoagulants. Due to its toxicity profile, its use as a senolytic in healthy individuals is currently unsafe and strictly experimental.